Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Trial Profile

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Antithymocyte globulin; Busulfan; Ciclosporin; Fludarabine; Methotrexate; Tacrolimus
  • Indications Graft-versus-host disease; Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Nov 2016 According to Incyte Corporation media release, data will be presented at 58th Annual American Society of Hematology (ASH) meeting 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top